TREATMENT FOR NEWLY DIAGNOSED STAGE D2 PROSTATIC CARCINOMA WITH HORMONAL THERAPY ALONE, OR CHEMOTHERAPY AGENTS IN COMBINATION WITH HORMONES
-
- Fujii Akio
- Department of Urology, Hyogo Medical Center for Adult Disease
-
- Oka Nobutoshi
- Department of Urology, Hyogo Medical Center for Adult Disease
-
- Miyasaki Shigenori
- Department of Urology, Hyogo Medical Center for Adult Disease
-
- Higuchi Akihiro
- Department of Urology, Hyogo Medical Center for Adult Disease
-
- Tomioka Osamu
- Department of Urology, Himeji Red Cross Hospital
-
- Morishita Shin-ichi
- Department of Urology, Himeji Red Cross Hospital
-
- Yamanaka Kunihito
- Department of Urology, Himeji Red Cross Hospital
-
- Itoh Noboru
- Department of Urology, Kobe Shakaihoken Chuo Hospital
-
- Okamoto Yasuyuki
- Department of Urology, Kobe Shakaihoken Chuo Hospital
-
- Tanaka Hiroyuki
- Department of Urology, Kobe Shakaihoken Chuo Hospital
-
- Yasuno Hirohiko
- Deparmtent of Urology, Hyogo Prefectural Awaji Hospital
-
- Okamoto Masayuki
- Deparmtent of Urology, Hyogo Prefectural Awaji Hospital
-
- Izumi Takehiro
- Department of Urology, Kasai City Hospital
-
- Yamada Yuji
- Department of Urology, Kasai City Hospital
-
- Matsushita Osami
- Department of Urology, Hyogo Prefectural Kaibara Hospital
-
- Iwamoto Takahiro
- Department of Urology, Hyogo Prefectural Kaibara Hospital
-
- Nakanishi Tateo
- Department of Urology, Ako City Hospital
-
- Ueno Koh-ichi
- Department of Urology, Ako City Hospital
-
- Nakamura Ichiro
- Department of Urology, Nishiwaki City Hospital
Bibliographic Information
- Other Title
-
- 新鮮 Stage D2前立腺癌に対する Hormone 単独療法あるいは Hormone・制癌剤併用療法
Search this article
Abstract
From June 1984 to March 1988, patients with newly diagnosed stage D2 prostate cancer were treated with protocol 1. This comprised oral hormonal agents either diethylstilbestrol diphosphate (Honvan: 300mg/day) or estramustine phosphate (Estracyt: 560mg/day), or chlormadinone acetate (Prostal: 100mg/day), plus intravenous cyclophosphamide (CPM, 0.5-1g/m2) every 3-4 weeks. From May 1988, protocol 2 was used in a randomized study of castration alone versus castration plus intravenous methotrexate (MTX, 20mg/m2) every 2 weeks. Forty-nine of 53 patients who underwent the two protocols were evaluable for the response. The response rates according to the NPCP criteria were 92% (11/12) for Honvan, 100% (9/9) for Estracyt, 78% (7/9) for Prostal and castration plus MTX, and 80% (8/10) for castration alone. There were no significant differences among these treatments. The median response duration and survival time (months) were 16 and 44, respectively, for Honvan, 19 and 37 for Estracyt, 12 and 43 for Prostal, 11 and 15 for castration plus MTX, and 13 and 13 for castration alone. The short survival times of the castration alone and castration plus MTX groups were due to a short follow-up period. There were no statistical differences among the oral hormonal agent plus CPM groups. However, the 2-year survival rate (Kaplan-Meier method) was higher in the CPM and MTX groups than in the castration alone group. Survival was longer in the good performance status (P. S.) group than the poor P. S. group (p<0.05 by Wilcoxon test) and in the responders than the non-responders (p<0.01). Side effects were not excessive in the chemotherapy groups and patient compliance was good.
Journal
-
- The Japanese Journal of Urology
-
The Japanese Journal of Urology 82 (10), 1656-1663, 1991
THE JAPANESE UROLOGICAL ASSOCIATION
- Tweet
Keywords
Details 詳細情報について
-
- CRID
- 1390001205056089472
-
- NII Article ID
- 110003085937
-
- NII Book ID
- AN00196577
-
- ISSN
- 18847110
- 00215287
-
- PubMed
- 1722834
-
- Data Source
-
- JaLC
- Crossref
- PubMed
- CiNii Articles
-
- Abstract License Flag
- Disallowed